Manhattan Scientifics, Inc. (MHTX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Manhattan Scientifics, Inc. (MHTX) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 46/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Manhattan Scientifics, Inc. (MHTX) Resumen de Asistencia Médica y Tuberías
Manhattan Scientifics, Inc. operates as a technology incubator specializing in nano-technologies and nano-medicine within the healthcare sector. The company focuses on the development and commercialization of life-enhancing technologies, primarily in the United States, facing competition from established medical device companies and other emerging technology firms.
Tesis de Inversión
Manhattan Scientifics, Inc. presents a high-risk, high-reward investment opportunity due to its focus on early-stage nano-technologies and nano-medicine. The company's success is contingent on its ability to successfully develop and commercialize its technologies, which face significant regulatory and market hurdles. With a market capitalization of $0.00B and a negative P/E ratio of -0.05, the company's valuation is highly speculative. Key value drivers include successful clinical trials and regulatory approvals for its nano-medicine technologies. Upcoming catalysts include potential partnerships and licensing agreements. Potential risks include the high beta of 9.94, indicating extreme volatility, and the challenges of operating in the competitive medical device industry.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Manhattan Scientifics operates as a technology incubator, focusing on early-stage development of nano-technologies and nano-medicine.
- The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
- Manhattan Scientifics has a negative P/E ratio of -0.05, indicating it is not currently profitable.
- The company's beta is 9.94, suggesting very high volatility compared to the market.
- Manhattan Scientifics does not offer a dividend, typical for growth-focused companies in the technology sector.
Competidores y Pares
Fortalezas
- Focus on innovative nano-technologies and nano-medicine.
- Potential for high growth in emerging markets.
- Early-stage access to promising technologies.
Debilidades
- Limited financial resources and small market capitalization.
- Dependence on successful development and commercialization of technologies.
- High risk associated with early-stage ventures.
Catalizadores
- Upcoming: Potential partnerships with pharmaceutical companies for drug delivery systems.
- Upcoming: Progress in clinical trials for nano-medicine applications.
- Upcoming: Regulatory approvals for new medical devices.
- Ongoing: Continued research and development in nano-technologies.
- Ongoing: Efforts to secure government funding and grants.
Riesgos
- Potential: Failure to obtain regulatory approvals for its technologies.
- Potential: Intense competition from established medical device companies.
- Potential: Limited financial resources to support research and development.
- Ongoing: High volatility in stock price due to its small market capitalization.
- Ongoing: Dependence on successful commercialization of its technologies.
Oportunidades de crecimiento
- Advancements in Nano-Medicine: The global nano-medicine market is projected to reach billions of dollars by 2030, driven by the increasing demand for targeted drug delivery and personalized medicine. Manhattan Scientifics can capitalize on this trend by focusing on developing innovative nano-medicine solutions for chronic diseases and cancer treatment. Successful clinical trials and regulatory approvals could significantly increase the company's valuation and market share. The timeline for realizing this opportunity depends on the progress of ongoing research and development efforts and the speed of regulatory reviews.
- Strategic Partnerships and Licensing Agreements: Manhattan Scientifics can accelerate its growth by forming strategic partnerships with larger pharmaceutical and medical device companies. These partnerships can provide access to funding, expertise, and distribution channels. Licensing agreements for its nano-technology platforms can generate revenue and validate the company's technology. The timeline for securing these partnerships depends on the company's ability to demonstrate the value and potential of its technologies. This strategy is ongoing as the company seeks to expand its network and market reach.
- Expansion into New Therapeutic Areas: Manhattan Scientifics can expand its focus beyond its current areas of interest and explore new therapeutic applications for its nano-technologies. This could include developing solutions for neurological disorders, cardiovascular diseases, and infectious diseases. The market for these therapeutic areas is substantial, and successful expansion could significantly increase the company's growth potential. This expansion is a long-term opportunity that requires significant investment in research and development.
- Government Funding and Grants: Manhattan Scientifics can leverage government funding and grants to support its research and development efforts. Government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF) offer grants for innovative research in nano-technology and nano-medicine. Securing these grants can provide non-dilutive funding and validate the company's technology. The timeline for securing these grants depends on the company's ability to submit competitive proposals and meet the eligibility criteria.
- Intellectual Property Protection: Manhattan Scientifics can strengthen its competitive advantage by securing strong intellectual property protection for its technologies. This includes filing patents for its nano-materials, drug delivery systems, and manufacturing processes. Strong intellectual property protection can prevent competitors from copying its technologies and provide a barrier to entry. This is an ongoing effort as the company continues to innovate and develop new technologies.
Oportunidades
- Strategic partnerships with larger pharmaceutical and medical device companies.
- Expansion into new therapeutic areas and applications.
- Government funding and grants for research and development.
Amenazas
- Intense competition from established medical device companies.
- Stringent regulatory requirements and lengthy approval processes.
- Potential for technology obsolescence and market disruption.
Ventajas competitivas
- Proprietary nano-technology platforms.
- Expertise in nano-medicine and targeted drug delivery.
- Early-stage access to innovative technologies.
Acerca de MHTX
Manhattan Scientifics, Inc., established in 1992 and based in New York City, functions as a technology incubator dedicated to the advancement and commercialization of life-enhancing technologies. The company's primary focus lies within the realms of nano-technologies and nano-medicine, where it seeks to develop and bring to market innovative solutions for various healthcare challenges. Originally named Grand Enterprises, Inc., Manhattan Scientifics has evolved to concentrate on identifying, developing, and commercializing early-stage technologies with high growth potential. The company's business model revolves around investing in and nurturing promising technologies until they reach a stage where they can be either spun off into separate entities, licensed to larger corporations, or further developed in-house. Manhattan Scientifics operates primarily within the United States, targeting opportunities where nano-scale technologies can provide significant improvements in medical treatments, diagnostics, and other healthcare applications. The company's success hinges on its ability to identify and develop groundbreaking technologies, navigate the complex regulatory landscape of the medical device industry, and secure the necessary funding to bring these innovations to market.
Qué hacen
- Develops nano-technologies for medical applications.
- Focuses on nano-medicine for targeted drug delivery.
- Incubates early-stage technologies with high growth potential.
- Seeks to commercialize life-enhancing technologies.
- Invests in promising technologies until they are ready for market.
- Aims to improve medical treatments and diagnostics through innovation.
Modelo de Negocio
- Invests in early-stage nano-technology and nano-medicine companies.
- Develops and commercializes innovative healthcare solutions.
- Generates revenue through licensing agreements and potential spin-offs.
Contexto de la Industria
Manhattan Scientifics operates within the medical device industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for nano-medicine is still in its nascent stages but is projected to experience significant growth in the coming years, driven by advancements in nanotechnology and increasing demand for targeted drug delivery systems. The company competes with established medical device companies and other emerging technology firms. Success in this industry requires significant investment in research and development, strong intellectual property protection, and the ability to navigate the complex regulatory landscape.
Clientes Clave
- Pharmaceutical companies seeking innovative drug delivery systems.
- Medical device manufacturers looking to incorporate nano-technologies.
- Healthcare providers seeking advanced diagnostic and treatment tools.
Finanzas
Gráfico e información
Precio de la acción de Manhattan Scientifics, Inc. (MHTX): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para MHTX.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para MHTX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para MHTX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de MHTX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Emmanuel Tsoupanarias
CEO
Emmanuel Tsoupanarias serves as the CEO of Manhattan Scientifics, Inc. His background includes experience in managing and developing early-stage technology companies. He has a track record of identifying and nurturing promising technologies in the healthcare sector. His expertise lies in strategic planning, business development, and financial management. He is responsible for overseeing the company's operations, driving its growth strategy, and building relationships with key stakeholders.
Historial: Under Emmanuel Tsoupanarias's leadership, Manhattan Scientifics has focused on advancing its nano-technology and nano-medicine initiatives. Key achievements include securing funding for research and development, forming strategic partnerships, and advancing the company's technology pipeline. He has also overseen the company's efforts to protect its intellectual property and navigate the regulatory landscape. His leadership is focused on driving innovation and creating long-term value for shareholders.
Información del mercado OTC de MHTX
The OTC Other tier represents the lowest tier of the OTC market, indicating that Manhattan Scientifics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies that are distressed, early-stage, or have chosen not to meet the listing requirements of higher tiers.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Potential for high price volatility due to low liquidity.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or investigations.
- Company has been in operation since 1992.
- Focus on developing innovative technologies in nano-medicine.
- CEO with experience in managing early-stage technology companies.
Acciones de Manhattan Scientifics, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar MHTX?
Manhattan Scientifics, Inc. (MHTX) actualmente tiene una puntuación IA de 46/100, indicando puntuación baja. Fortaleza clave: Focus on innovative nano-technologies and nano-medicine.. Riesgo principal a monitorear: Potential: Failure to obtain regulatory approvals for its technologies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de MHTX?
MHTX actualmente puntúa 46/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de MHTX?
Los precios de MHTX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre MHTX?
La cobertura de analistas para MHTX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en MHTX?
Las categorías de riesgo para MHTX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to obtain regulatory approvals for its technologies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de MHTX?
La relación P/E para MHTX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está MHTX sobrevalorada o infravalorada?
Determinar si Manhattan Scientifics, Inc. (MHTX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de MHTX?
Manhattan Scientifics, Inc. (MHTX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.